Virus‐like particles for vaccination against cancer

Mohsen, Mona O.; Speiser, Daniel E.; Knuth, Alexander; Bachmann, Martin F.

doi:10.1002/wnan.1579

Cited by 85 publications

(75 citation statements)

References 115 publications

(154 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The repetitive surface structure and a typical size range of 20–200 nm make VLPs highly immunogenic and they can induce a strong humoral and cellular immune response 1 . They can be utilized as vaccines against the virus they are derived from or can be used as nano-carriers displaying foreign antigens or cell targeting ligands for vaccine or therapeutic approaches (as reviewed in 2 – 4 ).…”

Section: Introductionmentioning

confidence: 99%

Covalent protein display on Hepatitis B core-like particles in plants through the in vivo use of the SpyTag/SpyCatcher system

Peyret

Ponndorf

Meshcheriakova

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Virus-like particles (VLPs) can be used as nano-carriers and antigen-display systems in vaccine development and therapeutic applications. Conjugation of peptides or whole proteins to VLPs can be achieved using different methods such as the SpyTag/SpyCatcher system. Here we investigate the conjugation of tandem Hepatitis B core (tHBcAg) VLPs and the model antigen GFP in vivo in Nicotiana benthamiana. We show that tHBcAg VLPs could be successfully conjugated with GFP in the cytosol and ER without altering VLP formation or GFP fluorescence. Conjugation in the cytosol was more efficient when SpyCatcher was displayed on tHBcAg VLPs instead of being fused to GFP. This effect was even more obvious in the ER, showing that it is optimal to display SpyCatcher on the tHBcAg VLPs and SpyTag on the binding partner. To test transferability of the GFP results to other antigens, we successfully conjugated tHBcAg VLPs to the HIV capsid protein P24 in the cytosol. This work presents an efficient strategy which can lead to time and cost saving post-translational, covalent conjugation of recombinant proteins in plants.

show abstract

Section: Introductionmentioning

confidence: 99%

Covalent protein display on Hepatitis B core-like particles in plants through the in vivo use of the SpyTag/SpyCatcher system

Peyret

Ponndorf

Meshcheriakova

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…VLPs represent a powerful and flexible tool for generation of the active components of cancer vaccines, as demonstrated in numerous preclinical studies (for review see [66]). We have already discussed the advantages of VLPs as vaccines, such as the multiplicity of antigens, the sizes of VLPs, which allow them to enter the lymphatic system, and their capability to encapsulate nucleic acids stimulating Toll-like receptors.…”

Section: Plant Vlp-derived Anticancer Vaccinesmentioning

confidence: 99%

“…As a result, VLPs are able to induce strong T cell responses, which is the most important requirement for a therapeutic vaccine against cancer. Moreover, VLP technology is already used for the prevention of cancer with Papilloma virus-derived VLPs, which efficiently protect immunized individuals against cervical cancer [66]. [67,68] and tested both vaccines in tumor challenge models.…”

Section: Plant Vlp-derived Anticancer Vaccinesmentioning

confidence: 99%

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines

Baļķe

Zeltiņš

2020

Viruses

View full text Add to dashboard Cite

Vaccination is one of the most effective public health interventions of the 20th century. All vaccines can be classified into different types, such as vaccines against infectious diseases, anticancer vaccines and vaccines against autoimmune diseases. In recent decades, recombinant technologies have enabled the design of experimental vaccines against a wide range of diseases using plant viruses and virus-like particles as central elements to stimulate protective and long-lasting immune responses. The analysis of recent publications shows that at least 97 experimental vaccines have been constructed based on plant viruses, including 71 vaccines against infectious agents, 16 anticancer vaccines and 10 therapeutic vaccines against autoimmune disorders. Several plant viruses have already been used for the development of vaccine platforms and have been tested in human and veterinary studies, suggesting that plant virus-based vaccines will be introduced into clinical and veterinary practice in the near future.

show abstract

“…The avian Newcastle disease virus (NDV) is a prototype OV that was used to develop cancer vaccines modified by virus infection. Virus-based cancer vaccines involving genetic engineering [3,4] is a different concept and it will not be discussed here.…”

Section: Introductionmentioning

confidence: 99%

New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection

Schirrmacher¹

2020

Biomedicines

View full text Add to dashboard Cite

The topic is how to achieve long-term protective anti-tumor immunity by anti-cancer vaccination and what are its mechanisms. Cancer vaccines should instruct the immune system regarding relevant cancer targets and contain signals for innate immunity activation. Of central importance is T-cell mediated immunity and thus a detailed understanding of cognate interactions between tumor antigen (TA)-specific T cells and TA-presenting dendritic cells. Microbes and their associated molecular patterns initiate early inflammatory defense reactions that can contribute to the activation of antigen-presenting cells (APCs) and to costimulation of T cells. The concommitant stimulation of naive TA-specific CD4+ and CD8+ T cells with TAs and costimulatory signals occurs in T-APC clusters that generate effectors, such as cytotoxic T lymphocytes and T cell mediated immunological memory. Information about how such memory can be maintained over long times is updated. The role that the bone marrow with its specialized niches plays for the survival of memory T cells is emphasized. Examples are presented that demonstrate long-term protective anti-tumor immunity can be achieved by post-operative vaccination with autologous cancer vaccines that are modified by virus infection.

show abstract

Virus‐like particles for vaccination against cancer

Cited by 85 publications

References 115 publications

Covalent protein display on Hepatitis B core-like particles in plants through the in vivo use of the SpyTag/SpyCatcher system

Covalent protein display on Hepatitis B core-like particles in plants through the in vivo use of the SpyTag/SpyCatcher system

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines

New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection

Contact Info

Product

Resources

About